• May 02, 2005 | Webcast

    Non-Invasive Assessments

    Harry Genant, M.D., Robert Heaney, M.D., Thomas Link, M.D., Sharmila Majumdar, Ph.D., Tony Keaveny, Ph.D.
    Skeletal Physiology, Molecular Cellular and Genetic Determinants of Bone Structure and Formation, Integrative Physiology of the Skeleton

    Moderator:
    Harry K. Genant, M.D., Department of Radiology, Osteoporosis and Arthritis Research Group, University of California at San Francisco, San Francisco, California, USA

    Speakers:

    Promises and Perils of the Widespread Use of DXA for Assessment of Fracture Risk
    Robert P. Heaney, M.D., Creighton University, Omaha, Nebraska, USA

    Current Methods and Clinical Utility of Macroarchitecture Measurements
    Thomas M. Link, M.D., Department of Radiology, University of California at San Francisco, San Francisco, California, USA

    Current Methods and Clinical Utility of Microarchitecture Measurements
    Sharmila Majumdar, Ph.D., Magnetic Resonance Science Center, Department of Radiology University of California at San Francisco, San Francisco, California, USA

    Remodeling and Skeletal Integrity: What Can Bone Turnover Markers (Existing or New) Tell Us About Fracture Risk and Treatment Efficacy?
    Pierre Delmas, M.D., Ph.D., Department of Rheumatology, The French National Institute of Medical Research (INSERM), Hopital Edouard Herriot, Lyon, France

    Combining In Vivo Assessments of Density and Geometry for Fracture Risk Assessment In Vivo
    Tony M. Keaveny, Ph.D., Department of Mechanical Engineering and Bioengineering, University of California at Berkeley, Berkeley, California, USA

    This meeting was sponsored by the American Society for Bone and Mineral Research (ASBMR) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    Supported by educational grants from Eli Lilly and Company, NPS Pharmaceuticals, Merck & Co., Inc., The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi-aventis, US), Novartis Pharmaceuticals Corporation, Amgen, Inc. and Wyeth Pharmaceuticals

    Length: 100 minutes

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details